LG Chem Acquires Technology for Non-Alcoholic Steatohepatitis Treatment Candidate from China
[Asia Economy Reporter Park So-yeon] LG Chem announced on the 18th that it has signed a contract to in-license TT-01025, a preclinical stage non-alcoholic steatohepatitis (NASH) treatment drug candidate, from China's Transthera Biosciences.
Under this contract, LG Chem secures global exclusive development and sales rights in the Americas and Europe, excluding China and Japan.
Transthera Biosciences will receive up to $350 million (approximately 417 billion KRW), including upfront payment and milestone payments based on development stages.
LG Chem plans to complete the preclinical experiments of TT-01025 within this year and start Phase 1 clinical trials in the United States from the first quarter of next year.
Hot Picks Today
![About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]](https://cwcontent.asiae.co.kr/asiaresize/93/2026051416263163580_1778743590.jpg)
About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- "Envious of Korean Daily Life"...Foreign Tourists Line Up in Central Myeongdong from Early Morning [Reportage]
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- Did Samsung and SK hynix Rise Too Much?... Foreign Assets Grow Despite Selling [Weekend Money]
This is LG Chem's second NASH treatment drug pipeline in-licensing. Previously, in March last year, LG Chem signed a contract with Sweden's Sprint Bioscience and is currently discovering candidate substances.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
